New Bladder-Sparing combo could change how we treat aggressive bladder cancer
NCT ID NCT06470282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for muscle-invasive bladder cancer that aims to save the bladder. It combines two drugs (enfortumab vedotin and pembrolizumab) with targeted radiation. About 47 adults with this cancer will receive the therapy to see if it can shrink tumors and avoid the need for bladder removal. The goal is to achieve a complete response, meaning no cancer is found after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Can One-Piece tumour removal improve bladder cancer outcomes?